Crossmark

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis

Crossref DOI link: https://doi.org/10.1186/s12905-025-03612-7

Published Online: 2025-02-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ji, Shiya

Chen, Xupeng

Yu, Yebo

Jia, Qiuping

Zhang, Xingxing

Gao, Zixin
License Information

Text and Data Mining valid from 2025-02-28

Version of Record valid from 2025-02-28
More Information

Article History

Received: 14 December 2024

Accepted: 17 February 2025

First Online: 28 February 2025

Declarations

:

: This is a systematic review and meta-analysis, ethics approval and consent to participate are not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below